NEW YORK, Feb. 16 (GenomeWeb News) - WellGen closed a $3-million Series B funding round, the company said today.
The capital will be used to begin clinical studies in humans under its obesity and inflammation programs, said the company in a statement.
The lead investor was Amphion Innovations. The company said investors included "new and existing shareholders."
Further details were not provided.
New Brunswick, NJ- based WellGen develops technologies to screen the effect of food on the expression of genes associated with human disease.